Divis Laboratories Ltd
NSE: DIVISLAB BSE: 532488
₹10037.50
-26.50 (0.26%)
Fri, 06 Nov 2026, 10:05 pm
Market Cap (in Cr)266264.97
PE Ratio91.10
Dividend0.30
Health Technology
Pharmaceuticals: Major
24.5KDivis Laboratories Ltd Company History
1990
- Divis Research Center (DRC) was established.
1991
- Divis Research Center successfully developed several commercial processes for intermediates and bulk actives and supplied to manufacturing majors.
1994
- Divis Research Center changed its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year.
1995
- The Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad started operations.
1997
- SGS-Yarsley of U.K certified Divis Laboratories as ISO-9002 compliant.
1999
- The European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced at Divis Laboratories.
2000
- The US-FDA successfully inspected Divis Laboratories.
- SGS-Yarsley of U.K awarded Divis the ISO 9001 Certification.
- SGS International AG of Switzerland awarded Divis the ISO-14001 Certification for its efficient Environment Management Systems.
2001
- BVQI of London awarded Divis the OHSAS-18001 Certification for its Occupational Health and Safety Management Systems.
2002
- Divis commenced the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam.
2003
- Divi's Laboratories opened a new research center called 'DRC-Vizag' for fundamental research in selected niche business core segments.
- The Company went for an IPO and listed on stock exchanges BSE, NSE, and HSE.
- The Company received a Certificate of Substantiability from the Council of Europe.
- Mr. A Narendra was appointed as Company Secretary & Compliance Officer of the Company.
2004
- The manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004.
- The US-FDA inspected the Choutuppal (Unit-1) for a second time with no 483.
2006
- The Company delisted its equity shares from The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006.
- The US-FDA inspected the Visakhapatnam (Unit-2) for the first time.
2007
- The Company split its face value from Rs10/- to Rs2/-.
2008
- The third US-FDA inspection for Choutuppal (Unit-1) took place.
2009
- The Company was certified and awarded for 'Best Green Belt Development'.
- The Company received the 'SURAKSHA PURASKAR' for the year 2008.
- The Company received the ISO 14001: 2004 re-certification for its Environment Management System.
- The Company gave a bonus in the ratio of 1:1.
2010
- Divis Lab set up a new unit in SEZ at Visakhapatnam.
- The Company recommended a dividend of 300% i.e. Rs. 6/- per equity share of Rs. 2/- face value for the year ended March 31, 2010.
2011
- Divi's Laboratories' stock surged 3.5 per cent in early morning trade on the Bombay Stock Exchange after the announcement of healthy growth in Q2 numbers.
2012
- The Board of Directors decided to seek shareholders' approval for the re-appointment and revision in remuneration of Mr. Madhusudana Rao Divi as Director-Projects of the Company.
- The Company re-appointed and revised the remuneration of Mr. Kiran S. Divi, Director & President-Operations of the Company.
- The remuneration of Dr. Murali K. Divi, Chairman & Managing Director of the Company, was enhanced.
- The remuneration of Mr. N. V. Ramana, Executive Director of the Company, was enhanced.
2013
- Divis Laboratories Ltd recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013.
2014
- Divis Laboratories Ltd recommended a dividend of 1000% i.e. Rs. 20/- per equity share of Rs. 2/- face value for the year ended March 31, 2014.
2015
- Divis Laboratories Ltd approved the issuance of bonus shares on the eve of its 25th year of formation, in the ratio of 1:1.
2016
- Divis Labs unit-2 at Chippada was successfully inspected by USFDA.
2017
- Divi's Laboratories reached a milestone of 11,000 employees and became one of the largest employers in the combined state of Telangana/Andhra Pradesh.
- Divi's Laboratories became one of the top 3 API manufacturers in the world and one of the top API companies in Hyderabad.
2018
- Divi's Laboratories' market capital reached $5B.
- The product portfolio was expanded to over 30 products.
- Divi's Laboratories' stock climbed nearly 2% on a rating upgrade.
2019
- Divi's Laboratories approved an additional investment of $250M towards expansion of production blocks in Unit-I and Unit-II.
- The 7th USFDA inspection in Unit 2 took place.
2020
- Commissioning of new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II occurred.
- US-FDA inspection of Unit-II at Village Chippada, Andhra Pradesh took place.
- Commencement of commercial production from DCV-SEZ Unit began.
- Construction of Divi's Laboratories Unit-III Facility near Kakinada commenced.
2021
- Ground breaking of the manufacturing plant in Kakinada took place.
2022
- Divi's Laboratories received the EHS excellence Award.
- Divi's Laboratories reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad.
2024
- Divi's Laboratories has a global presence in supplying APIs to more than 100 countries.
